Book Description:
Alzheimer’s disease (AD), the most common type of neurodegenerative disorder in the aging population, is characterized pathologically by extracellular amyloid plaques and intracellular neurofibrillary tangles, pathophysiologically by synaptic dysfunction, and clinically by a progressive dementia. The rapid progress in the research fields of AD and dementia continues since the publication of the first book volume with the same title. This second book volume contains 14 chapters, bringing together a presentation of research frontiers in current AD/dementia research. The topics range from defining deregulation of amyloid precursor protein (APP) processing and neurotransmitter and signal molecules involved in regulation of APP processing, transgenic AD mouse models and their relevance to AD research, amyloid -peptide (A) immunization, cerebral inflammation, myelin breakdown, roles of deregulation of cell cycle in AD pathology, relationship between cholesterol and AD, A binding to cholesterol and cholesterol oxidation, A-binding alcohol dehydrogenase and roles in AD pathogenesis, sex steroids, estrogen therapy for AD prevention, behavioral and psychological symptoms of AD, memantine for AD therapy, enoxaparin as a therapeutic agent for AD, to molecular links between AD and traumatic brain injury. The prospects for developing effective therapeutic agents that target memory-relevant AD pathogenesis, as shown in these chapters written by worldwide leaders in the fields, are more encouraging. The book will be highly valuable to students and scientists worldwide who are interested in the scientific research progress in AD and dementia

Table of Contents:
Preface:

Chapter 1.-Regulation of Synthesis and Metabolism of the Amyloid Precursor Protein by Extracellular Signals; pp. 1-26
(Barbara E. Slack, Boston University School of Medicine, and Richard J. Wurtman, Massachusetts Institute of Technology);

Chapter 2.-Modelling Alzheimer’s Disease: What can we Learn from Mice?; pp. 27-56
(Christopher Janus and Judith Wilson, Mayo Clinic Jacksonville);

Chapter 3.-Cerebral Inflammation and Alzheimer's Disease; pp. 57-96 (Parvathy Sarvanapavan, and Greer M. Murphy, Jr., Stanford School of Medicine);

Chapter 4.-Myelin Breakdown Trajectories and Risk Factors for Age-Related Cognitive Decline and Alzheimer’s Disease; pp. 97-107
(George Bartzokis, David Geffen School of Medicine at UCLA);

Chapter 5.-Alzheimer Disease: A Deregulated Cell Cycle Disease;
pp. 109-122
(Teresa A. Evans, Xiongwei Zhu, Hyoung-gon Lee, et al., Wuhan University, China );

Chapter 6.-Cholesterol, Statins and Alzheimer’s Disease: Past, Present and Future; pp. 123-135
(Benjamin Wolozin, Wesleyan University in Middletown, U.S.A.);

Chapter 7.-Cholesterol Oxidation and b-Amyloid: Perspectives on Alzheimer’s disease and Therapy; pp. 137-174
(Thomas J. Nelson, The Blanchette Rockefeller Neurosciences Institute);

Chapter 8.-ABAD: Mitochondrial Target for Aâ-Mediated Cellular Perturbation in Alzheimer Disease; pp. 175-189
(Shirley ShiDu Yan, Xi Chen, and Hao Wu, Columbia University U.S.A.);

Chapter 9.-The Role of Sex Steroids in Alzheimer’s Disease and Age-Related Cognitive Decline; pp. 191-226
(A. Yesufu, S. Bandelow and E. Hogervorst, Human Sciences Loughborough University,
U.K.);

Chapter 10.-Estrogen Therapy for Preventing Alzheimer's Disease: Therapeutic Strategies to Address Hormone Therapy Challenge for the Brain; pp. 227-249
(Liqin Zhao and Roberta Diaz Brinton, University of Southern California);

Chapter 11.-Behavioral and Psychological Symptoms of Alzheimer’s Disease; pp. 251-272
(Rajesh R. Tampi and Christopher H. van Dyck, Yale School of Medicine);

Chapter 12.-Memantine for Alzheimer’s Disease; pp. 273-306
(Abhilash K. Desai and George T. Grossberg, St. Louis University Health Science Center School of Medicine);

Chapter 13.-Enoxaparin as a Therapeutic Agent for Alzheimer’s Disease; pp. 307-326
(Luigi Bergamaschini, University of Milan, Italy, and Maria Grazia De Simon, Mario Negri Institute,Italy);

Chapter 14.-Head Injury and Dementia; pp. 327-355
(Kurt A. Jellinger, Vienna University School of Medicine, Austria);

Index